Table 2.
Information on the target population characteristics of FY2016 survivorship research grants (n = 165)*
| Characteristic | No. (%) |
|---|---|
| Cancer type† | |
| Breast | 78 (47.3) |
| Colorectal | 25 (15.2) |
| Prostate | 23 (13.9) |
| Hematologic‡ | 20 (12.1) |
| Gynecological§ | 13 (7.9) |
| Lung | 10 (6.1) |
| Head and neck | 9 (5.5) |
| Bladder | 6 (3.6) |
| Other‖ | 59 (35.8) |
| Pediatric or adult cancer survivors (at time of diagnosis) | |
| Pediatric survivors | 23 (13.9) |
| Adult survivors | 139 (84.2) |
| Both | 3 (1.8) |
| Sex | |
| Male | 9 (5.5) |
| Female | 71 (43.0) |
| Both | 85 (51.5) |
| Time since diagnosis | |
| Specified (categories below not mutually exclusive) | 127 (77.0) |
| <2 years of diagnosis | 106 (64.2) |
| 2 to 5 years after diagnosis | 31 (18.8) |
| >5 years after diagnosis | 27 (16.4) |
| Recurrent cancer survivors | 2 (1.2) |
| Not specified | 38 (23.0) |
| Special populations | |
| Adolescents and young adults | 11 (6.7) |
| Older adults (65 y or older) | 8 (4.8) |
| Rural populations | 5 (3.0) |
| Families (couples/dyads, parents/siblings) | 15 (9.1) |
*
FY = fiscal year.
†
Percent does not add up to 100% for cancer type, because some grants included multiple types of cancer.
‡
Includes lymphomas, leukemias, myeloma.
§
Includes cervical, endometrial, ovarian.
‖
Includes adult not otherwise specified, pediatric not otherwise specified, testicular, renal, bone, soft tissue, Wilms’ tumor, basal cell carcinoma, melanoma, brain, retinoblastoma, and gastrointestinal.